evipedia.ai
← Back

TB-500 for Health & Longevity

Evidence Review created on 10/27/2026 using AI4L / Opus 5.5

Also known as: Thymosin Beta-4 Fragment, Thymosin Beta-4 (17-23), Ac-LKKTETQ, LKKTETQ, TB500

Motivation

TB-500 is a laboratory-made peptide that copies a seven-amino-acid stretch of thymosin β4, a repair protein the body makes in almost every cell and releases from blood platelets at the site of an injury. It is sold online and through wellness clinics as an injection, marketed for recovery from tendon, muscle and joint injury.

Interest in the peptide grew out of laboratory and animal work on the full-length parent protein, which drew pharmaceutical development programs for wound and heart repair, and out of its adoption in sport, where it is a banned substance. Products sold under the name have been examined by chemists and by drug regulators in the United States and Canada, and the peptide was reviewed by a United States advisory committee in 2026.

This review examines what is actually known about TB-500 in the context of health and longevity: what the peptide is and how it is thought to act, which findings come from people and which from animals or cell work, how it is used in practice, what regulators have said, and where the main uncertainties lie.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and review articles that give a high-level overview of TB-500 and the repair protein it is derived from.

Content from three priority experts is not listed. Rhonda Patrick’s only coverage naming TB-500 is the members-only FoundMyFitness Q&A #64 episode (FoundMyFitness Q&A #64 episode page), which is not openly readable. Chris Kresser’s only mention is a single sentence in a guest podcast (Revolution Health Radio episode with Ben Greenfield), which is not substantial coverage. Lifespan.io returned no results for the peptide.

Grokipedia

Thymosin beta-4

Grokipedia has no stand-alone TB-500 article; its thymosin β4 article contains a dedicated TB-500 fragment section plus regulatory status, doping history and purity concerns as of 2026.

Examine

No Examine article exists for TB-500. Examine covers ingredients sold as dietary supplements, and TB-500 is an injectable unapproved drug (review: Moiz 2026) rather than a supplement ingredient, so it falls outside that scope.

ConsumerLab

Are Peptides Such as BPC-157 and TB-500 Safe and Effective?

ConsumerLab’s answer, last updated 7/30/2026, states that TB-500 cannot be legally sold in United States or Canadian dietary supplements and is not an approved drug, and tracks the 2026 regulatory moves.

Systematic Reviews

No systematic reviews or meta-analyses for TB-500 were found on PubMed as of 10/27/2026.

Neither side of the trade-off is represented: no systematic review or meta-analysis addresses TB-500’s claimed repair benefits or its principal risks — product adulteration and the tumour-biology signal of thymosin β4 — because no controlled human dataset exists to pool.

Mechanism of Action

TB-500 reproduces residues 17 to 23 of thymosin β4 (Tβ4), the body’s main actin-sequestering peptide, acetylated at one end to slow breakdown. Actin is the protein filament cells use to change shape and crawl. By binding single actin units, this short sequence frees cells to reorganize their internal scaffolding, letting skin, vessel-lining and progenitor (repair-precursor) cells migrate into a wound (review: Sosne 2010). The same seven-amino-acid sequence accelerated skin wound repair in aged mice (Philp 2003). Both are co-authored by Allan Goldstein, founder of rights holder RegeneRx.

Downstream, the parent protein activates integrin-linked kinase (an enzyme that relays signals from the cell surface) and Akt (a cell-survival switch) (Bock-Marquette 2004), and raises vascular endothelial growth factor (VEGF, the main driver of new blood-vessel growth) (Cha 2003).

Two mechanistic accounts compete. One holds that the fragment is the active core of the parent protein. The other casts it as a precursor: in-vitro work found Ac-LKKTETQ itself inactive in fibroblast (connective-tissue cell) wound closure, with activity traced to its metabolite Ac-LKKTE (Rahaman 2024). Two parent-protein activities, anti-inflammatory and scar-limiting signalling, arise from a different end of the molecule that TB-500 lacks.

Intravenous full-length Tβ4 clears fast, with peak levels at 3 to 15 minutes and a half-life of 0.5 to 2.08 hours in a study co-run by manufacturer Beijing Northland Biotech (Wang 2021). The fragment is cleaved by serum and tissue peptidases (protein-cutting enzymes) to Ac-LKKTE, Ac-LKK and Ac-LK, not by liver cytochrome (CYP) enzymes; distribution and selectivity in humans are unmeasured.

Historical Context & Evolution

Thymosin β4 was isolated from calf thymus in the 1960s and 1970s as part of a search for immune-regulating thymic hormones, and was chemically characterized in 1982 (Low 1982). Its original intended use was immune restoration, not tissue repair; that reframing followed its discovery in nearly all cells as the dominant actin-sequestering molecule.

The repair era began when the full-length protein accelerated skin and corneal healing in rodents, and when the short actin-binding sequence LKKTETQ was shown to reproduce much of that effect (Philp 2003). A 2004 report that the protein mobilized cardiac cells and limited damage after experimental heart attack in mice moved it into cardiology (Bock-Marquette 2004), followed by a 2007 report that it mobilized epicardial progenitors (repair-capable cells of the heart’s outer layer) (Smart 2007). RegeneRx Biopharmaceuticals, which holds the development rights and so a direct financial interest in its adoption, ran trials in skin ulcers, eye surfaces and heart muscle.

Two later findings narrowed rather than refuted the cardiac claims: mice engineered to lack the gene developed and functioned normally (Banerjee 2012), and cell tracking showed treatment after a heart attack thickened the epicardium and raised capillary density without turning those cells into heart muscle (Zhou 2012). The repair and blood-vessel effects survived; the regeneration-by-reprogramming interpretation did not.

Separately, a veterinary and gray-market product named TB-500, containing the acetylated fragment, appeared around 2010 and was characterized by doping laboratories (Ho 2012). This commercial path, not the pharmaceutical one, is how most people now encounter the peptide.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human outcome data exist for TB-500 itself, and the human trials of the full-length protein are single-sponsor studies in unrelated indications rather than replicated findings from independent groups.

Medium 🟩 🟩

No benefit reaches Medium: every human trial tests a different compound from the one sold as TB-500, which caps the grade at Low regardless of trial quality.

Low 🟩

Chronic Skin Ulcer Closure ⚠️ Conflicted

Topical full-length Tβ4 gel was tested in two manufacturer-run placebo-controlled trials, in venous stasis ulcers (leg ulcers from poor vein drainage) (Guarnera 2010) and pressure ulcers (NCT00382174). The venous report suggests possible benefit at 0.03%, but overall counts show no advantage over placebo. Indirect: topical full-length protein. Net reading: unproven.

Magnitude: 12 of 55 treated versus 4 of 17 placebo patients healed by day 84 in the venous ulcer trial (NCT00832091), and 8 of 54 versus 3 of 18 in the pressure ulcer trial (NCT00382174); neither posting reports a between-group comparison or confidence interval (the range the true value likely occupies).

Corneal Surface Healing ⚠️ Conflicted

A manufacturer-sponsored phase 3 trial of 0.1% Tβ4 eye drops in neurotrophic keratopathy (corneal breakdown from nerve damage) found a non-significant trend toward complete healing at four weeks; the Cochrane review judged it may not increase healing (low certainty) (Kruoch 2025). Indirect: topical full-length protein. Net reading: unproven.

Magnitude: 6 of 10 treated versus 1 of 8 placebo patients healed (Sosne 2022); the Cochrane review computes a risk ratio (how many times more often healing occurred with drops) of 9.00 (95% confidence interval 0.57 to 141.88), 18 participants (Kruoch 2025).

Dry Eye Signs and Symptoms ⚠️ Conflicted

A nine-patient phase 2 trial of RegeneRx’s drops reported less discomfort and corneal surface damage (Sosne 2015), but licensee ReGenTree’s 72-patient phase 2 (NCT01387347) and two phase 3 trials (NCT02974907; NCT03937882) missed their main outcomes. Indirect: topical full-length protein. Net reading: no established benefit.

Magnitude: change in ocular discomfort −0.4 with drops versus −0.4 with placebo, and inferior corneal staining −0.41 versus −0.46, in 700 participants at day 15, not compared between groups in the posted results (NCT03937882).

Cardiac Function After Heart Attack ⚠️ Conflicted

A 96-patient placebo-controlled trial of intravenous Tβ4 after stenting for heart attack found no difference in infarcted area (dead heart muscle) at 90 days; reduction appeared only in patients dosed within eight hours (Zhang 2025). Sponsor: manufacturer Beijing Northland Biotech. Indirect compound and route, so the net reading is unconfirmed.

Magnitude: direction favours early dosing only, holding when the first dose is given within eight hours of stenting; the report gives no outcome figure for the between-group difference in the full trial.

Speculative 🟨

Tendon Healing

TB-500 itself at 60 µg/kg daily improved tissue-structure scores and breaking strength in repaired rat Achilles tendons; combining it with BPC-157 added nothing (Biçer 2026). Rodent-only, no human tendon data.

Blood-Vessel Growth and Soft-Tissue Repair

Fragments spanning the actin-binding region promoted new vessel formation in cell culture and in animals (Dettin 2011). Basis is mechanistic; no controlled human study measures vessel growth or soft-tissue recovery after the fragment.

Hair Growth

The parent protein accelerated hair growth in rats and mice by mobilizing follicle stem cells (Philp 2004). Rodent-only and tested with the full-length protein; no human hair outcome has been measured.

Neural Repair and Memory

A different parent-protein fragment, Ac-SDKP, raised hippocampal neurogenesis (new nerve-cell formation) and spatial memory in mice (Kim 2015). TB-500 does not contain this sequence, so the basis is mechanistic and indirect only.

Benefit-Modifying Factors

  • Genetic variants: Thymosin β4 is encoded by the X-linked gene TMSB4X. No genetic variant has been linked to response, and no enzyme polymorphism is expected to matter because peptidases, not cytochrome enzymes, clear the fragment.

  • Baseline biomarker levels: Circulating Tβ4 varies widely between individuals, and is elevated in some disease states (Drum 2017). Whether a low baseline predicts greater response has never been tested.

  • Sex-based differences: No trial of any Tβ4 product reports sex-stratified efficacy. Because the gene sits on the X chromosome and plasma levels differ by sex in heart failure, a difference is plausible but unmeasured.

  • Pre-existing health conditions: Animal benefit was shown in impaired healing: the parent protein improved repair in diabetic and aged mice with delayed healing (Philp 2003). Healthy, well-recovering adults plausibly have the least headroom, though no study compared them.

  • Age: Repair benefit was shown in 26-month-old mice whose healing was delayed, consistent with repair capacity declining with age; no young-versus-old comparison was made. For older adults this widens the theoretical margin but not the evidence.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: there is no human adverse-event dataset for TB-500 at all, so no outcome has been documented in trials from more than one independent group.

Medium 🟥 🟥

No risk reaches Medium: the available human adverse-event data come from a different molecule given by different routes, which caps these items at Low.

Low 🟥

Injection-Site and General Adverse Events ⚠️ Conflicted

Repeated self-injection risks local reactions and infection, but phase 1 intravenous trials of full-length Tβ4 found adverse events mild to moderate and no more frequent than placebo (Wang 2021; RegeneRx-run Ruff 2010). Indirect: intravenous protein, not the fragment injected under the skin. Net reading: no excess over placebo.

Magnitude: any adverse event in 25 of 44 single-dose recipients (56.8%) versus 7 of 10 placebo recipients (70%), and 16 of 24 (66.7%) versus 5 of 6 (83.3%) on ten-day dosing.

Antibody Formation Against the Injected Peptide

Repeated injection of a foreign peptide can provoke anti-drug antibodies, which may neutralize the effect or drive reactions. In the recombinant full-length phase 1 program, positives were rare and transient (Wang 2021). Indirect: short intravenous courses, not months of injection under the skin.

Magnitude: 1 of 108 samples positive after single dosing and 2 of 56 after ten-day dosing, all reverting to negative at follow-up; the report gives no placebo-group rate for comparison.

Speculative 🟨

Mislabeled or Adulterated Product Content

Chemical analysis of TB500 and TB1000 products found contents inconsistent with their descriptions (Delcourt 2023), and Health Canada lists TB-500 among seized unauthorized injectables (Health Canada advisory). Basis is product analysis; no human outcome data.

Hypersensitivity and Severe Allergic-Type Reactions

A review of unregulated peptides lists contamination, manufacturing impurities and bacterial toxins as hazards (Moiz 2026); FDA flags immune-response risk from aggregation and impurities (FDA bulk drug substances list). Basis is mechanistic; no controlled data.

Tumour Growth and Spread ⚠️ Conflicted

Overexpressing thymosin β4 in mouse melanoma cells raised lung metastases (Cha 2003), while low expression predicted worse survival in myeloma (bone-marrow cancer) (Caers 2010). Direction depends on tumour type; no human exposure data exist.

Pathological Blood-Vessel Growth

A clinical review lists pathological blood-vessel growth among hazards of unregulated peptides (Moiz 2026); such growth drives proliferative retinopathy (abnormal retinal vessels) and wet macular degeneration (leaking vessels under the retina). Mechanistic only.

Transient Rise in a Tumour Marker

Squamous cell carcinoma antigen (a non-specific marker of skin-cell turnover) rose transiently in both treated and placebo volunteers in the phase 1 study and normalized (Wang 2021). An unvalidated biomarker shift, not a demonstrated harm.

Risk-Modifying Factors

  • Genetic variants: No variant is known to modify risk. Clearance is by peptidases, so variants in CYP3A4 or CYP2C9 (liver enzymes that break down many drugs) are not expected to alter exposure, and no study has tested genetic effects on response.

  • Baseline biomarker levels: A pre-existing elevation in tumour markers, or an unexplained abnormality on liver or kidney testing, removes the reference point needed to interpret any later change during use.

  • Sex-based differences: No sex difference in adverse events has been reported for any Tβ4 product. Baseline plasma levels differ by sex in heart failure populations (Drum 2017), so comparable exposure cannot be assumed.

  • Pre-existing health conditions: Active or recently treated cancer, proliferative diabetic retinopathy and neovascular macular degeneration are the conditions in which a pro-angiogenic (new-blood-vessel-promoting) peptide is most plausibly harmful, on mechanism rather than human data.

  • Age: Older adults carry more undetected early cancer and more retinal disease, which raises the consequence of an unmeasured pro-angiogenic effect even though no age-stratified safety data exist for any thymosin β4 product.

Key Interactions & Contraindications

Documented interactions:

  • None identified. No human interaction or pharmacokinetic (drug-level) study has tested TB-500, or the full-length protein, alongside another drug, so no interaction can be listed as documented.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Antiplatelet and anticoagulant drugs (clot-preventing medicines: aspirin, clopidogrel, apixaban, warfarin): inferred from reduced clot firmness when Tβ4 was added to blood exposed to an antiplatelet agent in vitro (Stark 2016). Possible extra bleeding or bruising; watching for unusual bruising is the practical step.

  • Supplements with antiplatelet activity (fish oil, ginkgo, high-dose vitamin E): inferred from the same reduced clot firmness in vitro (Stark 2016). Possible additive bruising or bleeding; watching for unusual bruising is the practical step.

  • Anti-angiogenic cancer therapy and intra-ocular anti-VEGF injections (bevacizumab, aflibercept, ranibizumab): inferred from opposing effects on vascular endothelial growth factor signalling. The peptide may blunt the intended vessel-suppressing effect; spacing doses apart is not expected to help, since both act on the same signalling.

  • Systemic corticosteroids (anti-inflammatory steroid medicines: prednisone, dexamethasone): inferred from the glucocorticoid-dependent generation of the anti-inflammatory Tβ4 sulfoxide and from corticosteroids’ own slowing of tissue repair. Possible blunting of any repair effect sought; no dose adjustment can be specified without human data.

  • Other peptides combined in the same cycle (BPC-157, GHK-Cu, ipamorelin): inferred from shared repair and angiogenic pathways, and flagged by an advisory committee member (Healio report; FDA minutes pending, FDA meeting page). Combining makes any adverse event impossible to attribute; single-agent use avoids this.

Populations who should avoid TB-500:

  • Anyone with active, metastatic or recently treated cancer: inferred from the metastasis-promoting effect of thymosin β4 overexpression in mouse melanoma (Cha 2003) and raised as a voting concern at the 2026 advisory committee (Healio report; FDA minutes pending, FDA meeting page); no human data.

  • People with proliferative diabetic retinopathy or neovascular macular degeneration: inferred from the peptide’s pro-angiogenic mechanism in tissue where new vessels cause bleeding and vision loss; no human data.

  • Pregnant or breastfeeding people: inferred from the peptide’s effects on cell migration and new vessel growth, processes central to fetal development, and from the absence of any reproductive or lactation data for any thymosin β4 product; no human data.

  • Competitive athletes under an anti-doping code: TB-500 is prohibited under class S2 of the 2027 prohibited list (USADA 2027 advisory); this is a regulatory rather than a medical exclusion.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Independent third-party assay before use: a lot-specific certificate of analysis for identity, purity and bacterial toxins (endotoxin) is requested, and material without one is rejected. This addresses the mislabeling and contamination risk found in marketed TB500 products.

  • Single-agent cycles: one peptide is used at a time rather than a blend, so that any reaction can be attributed. This addresses the attribution problem created by multi-peptide blends.

  • Baseline and post-cycle laboratory testing: liver enzymes, kidney function and a blood count are checked before starting and after 8 to 12 weeks, so an organ-level problem is detected rather than assumed absent.

  • Age-appropriate cancer screening completed first: colorectal, breast, cervical, prostate and skin screening is completed before any cycle, given that the tumour-biology signal for thymosin β4 is unresolved and exposure in undetected disease is uncharacterized.

  • Dilated retinal examination for anyone with diabetes: the examination establishes whether proliferative retinopathy is present before exposure to a pro-angiogenic peptide, since new vessel growth in the retina causes bleeding and vision loss.

  • Lowest workable dose and shortest cycle: exposure is limited to a defined 4 to 6 week block rather than continuous use, reducing cumulative exposure to a compound with no long-term human safety data.

  • Sterile technique and single-use supplies: alcohol-prepped skin, a new needle per injection and bacteriostatic water within its stated shelf life are used, mitigating injection-site infection and abscess from repeated self-injection.

Therapeutic Protocol

Each dose below is cited to its source. Other parameters, such as timing, cycling and titration steps, reflect common practice rather than published evidence, because no human dosing study of TB-500 exists.

  • No validated human dose: reviews written for sports-medicine clinicians state plainly that indication, dose, frequency and duration for TB-500 remain unknown (Mayfield 2026). Any figure in circulation is practice, not evidence.

  • Circulating gray-market regimen: an affiliate site earning commissions from peptide suppliers describes about 2 to 2.5 mg under the skin twice weekly for 4 to 6 weeks, then once weekly (PeptideDosingProtocols TB-500 protocol page). No trial supports these numbers.

  • Doses actually tested in people, for contrast: intravenous full-length Tβ4 at 42 to 1260 mg single and 14-day dosing (Ruff 2010), and 0.05 to 25 µg/kg intravenously (Wang 2021). Different molecule, different route.

  • Doses tested in animals: TB-500 60 µg/kg daily intraperitoneally (into the abdominal cavity) for tendon repair in rats (Biçer 2026), and full-length Tβ4 with an estimated optimal 3.75 mg/kg in a rat stroke model (Morris 2014).

  • Competing approaches, no default: for tendon and joint complaints, the alternatives with human trial evidence are loading-based rehabilitation, platelet-rich plasma and surgery; peptide reviews conclude peptides should not replace or supplement standard orthopaedic care (Tewari 2026).

  • Expert and clinic origin: no single originator is documented; community dosing guides spread the regimen. Peptide clinician William Seeds (Redox Medical Group) co-authored a 2026 orthopaedic review concluding clinical trials are lacking (Rahman 2026).

  • Half-life: intravenous full-length protein peaks at 3 to 15 minutes with a 0.5 to 2.08 hour half-life (Wang 2021); the fragment is cleaved to Ac-LKKTE, Ac-LKK and Ac-LK, with Ac-LKK detectable in rats to 72 hours (Rahaman 2024).

  • Single versus split dosing: because the parent molecule clears within hours while its metabolites persist for days, splitting a weekly amount across two injections is the common choice; no pharmacokinetic study in people compares split with single administration.

  • Best time of day: no time-of-day data exist for this peptide. Practice places injections in the evening on the reasoning that repair signalling overlaps sleep, which is a rationale rather than a finding.

  • Genetic polymorphisms: no genetic marker guides dose. Variants in APOE4 (cholesterol transport), MTHFR (folate processing) or COMT (dopamine breakdown), which matter for other interventions, have no demonstrated relevance to a peptidase-cleared peptide.

  • Sex-based differences: no dosing difference is established. Trials of thymosin β4 products have not reported sex-stratified dose-response, so the same amounts are used in practice for men and women.

  • Age considerations: animal repair effects were shown in aged mice, but no human dose has been established at any age. For older adults the relevant adjustment is completing cancer and retinal screening first, not changing the amount.

  • Baseline biomarker levels: no biomarker predicts response, and none is used to set the dose. Baseline testing serves safety comparison rather than dose selection.

  • Pre-existing health conditions: impaired-healing states were where animal benefit was shown, while cancer, proliferative retinopathy and bleeding disorders are where practice avoids the compound entirely rather than reducing the dose.

Discontinuation & Cycling

  • Intended duration: use is framed as short-term and injury-linked, not lifelong. No trial has tested injected dosing beyond 14 days in people; topical gel alone ran to 84 days (NCT00832091), so open-ended injected use has no safety basis.

  • Cycling practice: typical practice runs a 4 to 6 week loading block, an optional lower-frequency maintenance block, then a 4 to 8 week break. No human data show cycling preserves any effect.

  • Withdrawal effects: none have been described. The peptide does not act on a hormonal axis that could be suppressed, so abrupt cessation is not expected to produce rebound or deficiency.

  • Tapering: no taper is needed or described. Because the molecule and its metabolites clear within days, stopping outright is the practice, and no tapering protocol has been published.

  • Stopping for a planned event: athletes under anti-doping codes cannot cycle their way to compliance: the substance is prohibited under class S2 (USADA 2027 advisory), and doping laboratories detect its metabolites (Ho 2012).

Sourcing and Quality

  • No legal consumer source exists: TB-500 is not an approved drug in the United States (review: Moiz 2026), and Health Canada lists it among seized unauthorized injectable drugs (Health Canada advisory), so every retail vial reaches the buyer through a research-chemical or offshore channel.

  • Compounding status: FDA moved thymosin beta-4 fragment off its category 2 list after the nomination was withdrawn, not on a safety finding (FDA bulk drug substances list); an advisory committee then voted for listing (Healio report; FDA minutes pending, FDA meeting page).

  • What to look for: a lot-specific certificate of analysis from an independent laboratory covering identity by mass spectrometry, purity above 98%, and endotoxin and sterility testing. Vials labelled research use only carry no such assurance by default.

  • Documented content problems: analysis of marketed TB500 and TB1000 found contents inconsistent with their descriptions, and a companion product was largely sheep extracellular matrix (Delcourt 2023). Label text is not evidence of contents.

  • Reputable channels, where any apply: only FDA-registered outsourcing facilities or state-licensed compounding pharmacies offer verifiable quality; TB-500 was still only under consideration for the 503A bulks list in July 2026, so neither has an established lawful basis to supply it (FDA meeting page).

  • Reconstitution and storage: freeze-dried (lyophilized) powder is kept refrigerated and reconstituted with bacteriostatic water, then refrigerated and used within weeks. Repeated puncture of a non-preserved vial invites contamination, which matters more for an unsterile-sourced product.

Practical Considerations

  • Time to effect: no human timeline exists. In rat tendon repair, differences appeared at four weeks (Biçer 2026); users typically judge effect within a 4 to 6 week block, which is also the window in which natural healing occurs.

  • Common pitfalls: attributing ordinary recovery to the peptide, combining several peptides at once, buying on price alone, and skipping baseline testing so that a later abnormal result cannot be interpreted.

  • Regulatory status: not approved in the United States (review: Moiz 2026) and unauthorized in Canada (Health Canada advisory). The FDA’s July 2026 advisory committee reviewed TB-500 (FDA meeting page); staff reviewers recommended against listing (Healio report; FDA minutes not yet posted).

  • Advisory committee outcome: the committee voted 8-6 with one abstention to recommend listing, against its own reviewers’ proposal (Healio report; FDA minutes not yet posted, FDA meeting page).

  • Anti-doping consequence: prohibited under class S2 of the 2027 prohibited list (USADA 2027 advisory), so any tested athlete faces an anti-doping sanction rather than only a health trade-off.

  • Cost and payer incentives: no insurer or national health system covers TB-500, while rehabilitation and surgery for the same complaints are covered; that asymmetry gives payers no stake in studying it and leaves sellers as the main funders of promotional content.

  • Access: material is easy to obtain online and hard to verify, the opposite of the usual accessibility problem. Price per cycle is modest relative to clinic-administered alternatives, which is part of its appeal.

Interaction with Foundational Habits

  • Sleep: no direct interaction is documented, and the peptide has no known effect on sleep architecture. Indirectly, growth and repair signalling concentrates during slow-wave sleep, so protecting sleep duration is the practical consideration during any repair-focused cycle.

  • Nutrition: no direct interaction. Indirectly, collagen synthesis depends on adequate protein, vitamin C and zinc, and the actin-remodelling mechanism cannot compensate for a protein deficit; practice pairs cycles with roughly 1.6 g protein per kg body weight daily.

  • Exercise: potentially potentiating, by mechanism rather than measurement. Tendon and muscle remodelling is driven by progressive mechanical loading, and the peptide’s proposed role is cell migration into an already-loaded repair site; it is not a substitute for rehabilitation loading.

  • Stress management: indirect and bidirectional. Glucocorticoids generate the anti-inflammatory sulfoxide form of thymosin β4, linking stress hormones to the peptide’s inflammation-related activity, while chronically high cortisol independently slows wound healing. No human study measures this interaction.

Monitoring Protocol & Defining Success

Before any cycle, practice establishes a baseline that makes a later abnormal result interpretable: liver enzymes, kidney function with estimated filtration rate, a complete blood count, and high-sensitivity C-reactive protein. Because the tumour-biology signal for thymosin β4 is unresolved, age-appropriate cancer screening and, for anyone with diabetes, a dilated retinal examination belong in the same baseline. The laboratory panel is repeated once during a cycle, at around four weeks, and again at its end, usually 8 to 12 weeks, then every 6 to 12 months if use continues. No biomarker tracks whether TB-500 is working; monitoring exists to catch harm and to document that nothing changed. Success is therefore defined functionally, against the specific injury or complaint that prompted use, not by any laboratory value.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7-56 U/L (standard reference range) Safety check: a rise during use stops or pauses the cycle ALT: alanine aminotransferase, a liver enzyme; fasting not required; pair with AST (aspartate aminotransferase, a second liver enzyme) and bilirubin; intense exercise raises it independently
Creatinine with eGFR Creatinine: men 0.74-1.35 mg/dL, women 0.59-1.04 mg/dL (standard reference range) Safety check: detects kidney injury from an unverified injected product eGFR: estimated glomerular filtration rate, a kidney-function measure calculated from creatinine and reported alongside it; heavy protein or creatine loading the day before skews results; interpreted against the individual’s own baseline
Complete blood count (white cell count) 4.0-11.0 ×10⁹/L (standard reference range) Safety check: flags infection from self-injection and unexplained blood-count shifts Fasting not required; a rise with injection-site pain or fever means stopping and seeking care
hs-CRP 0.0-3.0 mg/L (standard reference range) Safety check: a rise flags infection or an inflammatory reaction to an unverified injected product hs-CRP: high-sensitivity C-reactive protein, a general inflammation marker; invalid within two weeks of infection, injury or hard training; risk-category cutoffs are not reference ranges

Qualitative markers to track alongside the laboratory panel:

  • Pain at the injured site, scored the same way each week rather than recalled
  • Range of motion and loaded function, such as single-leg hop or overhead reach
  • Return to a specific activity at a specific load, defined before the cycle starts
  • Injection-site appearance: redness, swelling, lumps or persistent soreness
  • Any new skin lesion, mole change, or visual symptom, which prompts stopping

Emerging Research

  • Ophthalmic phase 3 in neurotrophic keratopathy: SEER-2, sponsored by licensee ReGenTree, randomized participants to 0.1% thymosin β4 drops (NCT05555589). Last patient visit completed August 2026, topline results expected November 2026, none yet posted (EDAILY report).

  • What SEER-2 would change: a positive result would strengthen the corneal-healing item and the parent protein’s repair claim generally; a null result would align it with the failed dry-eye phase 3 programme and weaken the read-across to injected use.

  • Cardiac programme after heart-attack stenting: a 90-participant phase 2 of manufacturer Beijing Northland Biotech’s recombinant thymosin β4 completed May 2023 with no results posted (NCT05984134), and a 189-participant phase 2 was registered as not yet recruiting (NCT07586865). A positive result would lift the cardiac item; a null result would close it.

  • Research that could weaken the case: the finding that the fragment may be inactive until cleaved to Ac-LKKTE (Rahaman 2024) invites head-to-head work on fragment versus metabolite; if confirmed, the marketed molecule is the wrong one.

  • Unresolved tumour biology: work on fragment-driven cancer-cell migration (Yoon 2021) against tumour-suppressive findings in myeloma (Caers 2010) means the direction of risk is unsettled, and no human exposure registry exists to resolve it.

  • Regulatory research gap: the FDA identified no human exposure data for TB-500 itself (FDA bulk drug substances list), so the near-term literature that matters most is any first-in-human pharmacokinetic and safety dataset for the fragment, not more rodent repair models.

Conclusion

TB-500 is a short laboratory-made copy of part of a repair protein the body already produces, sold as an injection for faster healing. The gap between its reputation and its evidence is unusually wide. No human study has ever tested the molecule that is sold under this name. Every human finding cited for it comes from the full-length parent protein, given by a different route for a different purpose, and that evidence is itself mixed: eye-drop programmes for dry eye missed their main targets, skin-ulcer trials showed no clear advantage over placebo, and a heart trial found no overall difference. Animal and laboratory work is more encouraging and more consistent, including a rat tendon study of the actual compound, but it stays at the level of mechanism.

The risks are mostly about what is in the vial rather than the peptide itself. Products carrying this name have been found not to match their labels, there is no lawful consumer supply, and regulators in both the United States and Canada have acted on that. A separate and unresolved question is whether encouraging cells to migrate and new vessels to grow is wise in anyone with undetected cancer or eye disease. Most supporting trials were run by companies developing the protein commercially, and most promotional material comes from sellers. For an informed adult weighing this, the honest summary is an appealing mechanism, no direct human evidence, and an unverifiable product.

Top - Benefits - Risks - Protocol